Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline ...
WEB3 days ago · Oct. 2, 2024, 11:55 PM. J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares ...
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
WEBGet the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
GSK shares tumble after Delaware court ruling on Zantac
WEBJun 3, 2024 · GSK shares dropped almost 10 per cent on Monday after a ruling from a Delaware judge left the UK drugmaker exposed to US jury trials over its allegedly carcinogenic heartburn treatment Zantac.
GSK sees strong growth as Haleon split and vaccine drive pays ...
WEBJan 31 (Reuters) - GSK (GSK.L) beat market estimates for fourth-quarter results on Wednesday, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs...
US FDA approves GSK’s AREXVY, the world’s first respiratory ...
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK makes a strong start to 2024 with improving outlook for ...
WEBMay 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
GSK delivers strong 2023 performance and upgrades growth ...
WEBJan 31, 2024 · Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion.
GlaxoSmithKline News | GSK News - NewsNow
WEBNewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications.
GSK lifts annual forecasts again, powered by strong vaccine ...
WEBNov 1, 2023 · GSK raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its respiratory syncytial virus (RSV) vaccine in the United States.